GSK, Chroma in potential $1B deal over anti-inflammatory drugs

06/23/2009 | Reuters

GlaxoSmithKline is teaming up with Chroma Therapeutics to secure rights to the latter's small-molecule compounds that target macrophages to treat inflammatory diseases such as rheumatoid arthritis. Chroma could receive more than $1 billion out of the deal depending on the success of the four drug programs, which employ its proprietary esterase-sensitive motif technology to enhance drug delivery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA